Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer.


Journal article


Kristina Golfmann, Lydia Meder, Mirjam Koker, Caroline Volz, Sven Borchmann, Lars Tharun, Felix Dietlein, Florian Malchers, Alexandra Florin, Reinhard Büttner, Neal Rosen, Vanessa Rodrik-Outmezguine, Michael Hallek, Roland T Ullrich
Oncogene, vol. 37(42), 2018 Jun 3, pp. 5682-5693

Cite

APA
Golfmann, K., Meder, L., Koker, M., Volz, C., Borchmann, S., Tharun, L., … Ullrich, R. T. (2018). Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. Oncogene, 37(42), 5682–5693.

Chicago/Turabian
Golfmann, Kristina, Lydia Meder, Mirjam Koker, Caroline Volz, Sven Borchmann, Lars Tharun, Felix Dietlein, et al. “Synergistic Anti-Angiogenic Treatment Effects by Dual FGFR1 and VEGFR1 Inhibition in FGFR1-Amplified Breast Cancer.” Oncogene 37, no. 42 (June 3, 2018): 5682–5693.

MLA
Golfmann, Kristina, et al. “Synergistic Anti-Angiogenic Treatment Effects by Dual FGFR1 and VEGFR1 Inhibition in FGFR1-Amplified Breast Cancer.” Oncogene, vol. 37, no. 42, June 2018, pp. 5682–93.